Addressing the needs of people with extensively drug-resistant TB through pre-approval access to drugs and research-Reference-Cited by-同舟云学术

Addressing the needs of people with extensively drug-resistant TB through pre-approval access to drugs and research

Published:2023-12-01 Issue:4 Volume:13 Page:126-129
ISSN:2220-8372
Container-title:Public Health Action
language:en
Short-container-title:public health action

Author:

Stillo J.¹,Frick M.²,Galarza J.³,Kondratyuk S.⁴,Makone A.⁵,McKenna L.²,Vandevelde W.⁶,Winarni P.⁴,Agbassi P.⁴

Affiliation:

1. Department of Anthropology, Wayne State University, Detroit, MI, USA, Global Tuberculosis Community Advisory Board, New York, NY, USA

2. Global Tuberculosis Community Advisory Board, New York, NY, USA, Treatment Action Group, New York, NY, USA

3. Global Tuberculosis Community Advisory Board, New York, NY, USA, McGovern Medical School at the University of Texas Health Science Center, Houston, TX, USA

4. Global Tuberculosis Community Advisory Board, New York, NY, USA

5. Global Tuberculosis Community Advisory Board, New York, NY, USA, Department of Political Science, Stellenbosch University, Cape Town, South Africa

6. Global Tuberculosis Community Advisory Board, New York, NY, USA, GNP+, Cape Town, South Africa

Abstract

Multiple therapeutic options exist for people with drug-resistant TB (DR-TB), but there is an urgent need to improve access to novel compounds and regimens for people with difficult to treat forms of TB. In additional to formal research studies and clinical trials, other mechanisms of accessing promising new TB compounds need to be introduced as soon as these drugs have shown efficacy and safety in phase II trials. Pre-approval access programs for newer TB drugs such as bedaquiline, delamanid, and pretomanid all suffered from shortcomings. These can be addressed for the next generation of new TB drugs through a series of concerted actions by stakeholders at multiple levels. In this viewpoint, we advocate for transparent, accessible pre-approval access as a core element of person-centered care for DR-TB.

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Public Health, Environmental and Occupational Health,Health Policy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Novel Antimicrobial Compounds Targeting Mycobacterium tuberculosis S-Adenosyl-L-Homocysteine Hydrolase Using Dual Hierarchical In Silico Structure-Based Drug Screening;Molecules;2024-03-14